Dan O’Day:
Now moving forward, I mean, obviously our emphasis is on growth it's on long-term growth. It's on our ability to shape that R&D portfolio into an area where we have a good number of innovative medicines balanced across our stages of development. As we spoke about last time, one of the areas that we really need to continue to strengthen is our late-stage portfolio as well.
And I do think that the collaboration with Galapagos and some of the acceleration of molecules that we have within Gilead will help us to strengthen that late-stage portfolio. I remind you with Galapagos they have two products that are in later stage; one for IPF and one for osteoarthritis in addition to the broad program around Filgotinib.
…
And we'll continue to supplement that with innovation from the outside, innovation network like Galapagos. Secondarily, on Galapagos in particular, I think, it's probably the best way to put it into context and I said this on the call previously with Galapagos, it's with the collaboration with Galapagos we essentially double our research capacity. And what does that mean? I mean, we've got roughly the same number of scientific colleagues across the two organizations.
In fact Galapagos will be increasing their number to get a little closer to what we have at Gilead, but it provides with two sources of early-stage discovery input into our late-stage portfolio. And I think that's very exciting because if we can get two highly productive research engines speeding the late-stage portfolio that speaks well for kind of the future of our portfolio as we move forward.
…
I can say that as we partner with Galapagos, the respect and admiration from a scientific perspective between Gilead and Galapagos was very high and that's what led me with confidence to move forward with the team in striking that deal.
So, we will be driven by science for sure. We'll focus on the areas of expertise that we have today. I mean that's HIV, oncology, liver disease, inflammation, and the intersections between those two.
To your point, I mean I don't think we'll have a one-size-fits-all strategy for bringing innovation into the company. I think that the Galapagos structure was the right structure for that collaboration. It allowed independence, it allowed us to secure our investment, it allowed us rights to everything that comes out of that investment, and therefore, that collaboration was fit for purpose for that particular transaction.
John McHutchison
Sure. So, first of all to start off with filgotinib, getting to the issue of -- issues across all thrombotic events, we are still very pleased with the results across all those events, and don't really see anything that would change our perspective on that compared to the specific data that we've presented already.
Moving on to the Galapagos compound, as you might imagine, we looked very carefully at all of the available data in the IPF program. We have quite a bit of experience in IPF ourselves with prior programs at Gilead as well. And we saw that the data really provided the confidence to Galapagos to be able to move ahead and we share that confidence with them.